# ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)

> **NIH NIH UG1** · SLOAN-KETTERING INST CAN RESEARCH · 2021 · $892,711

## Abstract

PROJECT SUMMARY
The proposed Leukemia Translational Science Center (LTSC), will generate, coordinate and lead translational
studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will
serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the
Leukemia Translational Laboratory (LTRL) and the Leukemia Tissue Bank (LTB), and a comprehensive
Leukemia Data Warehouse. The LTSC is led by R. Levine, A. Melnick, and A. Ferrando. They have developed
an extensive track record in translational research leadership and implementation of state-of-the-art correlative
studies in leukemia biology. The LTSC is further enhanced through its partnership with the MSK Centers for
Molecular Oncology and Center for Hematologic Malignancies, which provide access to high-throughput
genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to
perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality
clinical trials based on the most important science, the LTSC will establish an interaction framework that will
attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians
and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for
cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including
access to patient samples and clinical/molecular data, genomic and epigenetic profiling capabilities and
analytic platforms, scientific support, and a robust, productive collaborative leukemia research community. In
this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia
clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop
innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the
LTSC aims to transform the standard practice of leukemia care with the development and implementation of
personalized diagnostic methods, biomarkers and therapies.

## Key facts

- **NIH application ID:** 10148734
- **Project number:** 5UG1CA233332-03
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** Adolfo A. Ferrando
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $892,711
- **Award type:** 5
- **Project period:** 2019-03-07 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148734

## Citation

> US National Institutes of Health, RePORTER application 10148734, ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) (5UG1CA233332-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148734. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*